Search clinical trials for: JNJ-40411813

Total 873 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

Schizophrenia

Germany, Spain, Bulgaria, Romania, Austria, Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers

Healthy
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-40411813 in Healthy Japanese Male Participants

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

Healthy

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Ketamine Challenge Study With JNJ-40411813

Confusion | Schizophrenia | Perceptual Disorders

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

Major Depressive Disorder

Ukraine, Bulgaria, Romania, Russian Federation, Hungary, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Focal Onset Seizures

Germany, Korea, Republic of, Belgium, United States, Russian Federation, Poland, Ukraine, Spain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

Healthy

Germany
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen Cilag N.V./S.A.

Completed

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Healthy

Netherlands
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Tangent Data
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive (JNJ-DEP)

Depression

Moldova, Republic of, Romania
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Healthy

United States
The First Affiliated Hospital with Nanjing Medical...
Xian-Janssen Pharmaceutical Ltd.

Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Israel, Korea, Republic of, Netherlands, Belgium, Australia, Poland, Spain, France, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Netherlands, Germany
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Obesity and Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Healthy

Netherlands
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Advanced Solid Tumors

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers

Health

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Suspended

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Healthy

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma

Asthma
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA)

Advanced Solid Malignancies

United States, United Kingdom, Canada, Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

Healthy

United States
Janssen R&D Ireland

Completed

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

Alzheimer Disease

Spain, Netherlands, Belgium, Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

Healthy

United States

3

Subscribe